CHROMOSOME-NUMBER CORRELATES WITH SURVIVAL IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA

被引:8
作者
TIAINEN, M
RAUTONEN, J
PYRHONEN, S
TAMMILEHTO, L
MATTSON, K
KNUUTILA, S
机构
[1] UNIV HELSINKI,CENT HOSP,DEPT PEDIAT,SF-00100 HELSINKI 10,FINLAND
[2] UNIV HELSINKI,CENT HOSP,DEPT RADIOTHERAPY & ONCOL,SF-00100 HELSINKI 10,FINLAND
[3] UNIV HELSINKI,CENT HOSP,DEPT PULM MED,SF-00100 HELSINKI 10,FINLAND
关键词
D O I
10.1016/0165-4608(92)90031-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Modal (MO) and mean (ME) chromosome numbers determined by cytogenetic analysis were compared with survival in 34 patients with diffuse malignant pleural mesothelioma. The patients with normal chromosome number and no clonal abnormalities (MO = 46) survived longer (median survival 17 months) than patients with clonal abnormalities. MO > 46 correlated with shorter survival (median 12 months) (p = 0.0186). The correlation was more clear between mean chromosome number (ME) and survival: the median survival of patients with ME > 46 was 13 months whereas that of the patients with ME < 46 was 26 months and ME = 46 (normal chromosome number and no clonal abnormalities) 31 months (p = 0.0007). Furthermore, there was a tendency of an association between ME = 46, ME < 46 and epithelial subtype reported to be associated with a favorable prognosis in mesothelioma. The addition of chromosome material may present a mechanism to enhance expression of genes important in the pathogenesis of mesothelioma and lead to more aggressive behavior of the tumor.
引用
收藏
页码:21 / 24
页数:4
相关论文
共 17 条
[1]   MALIGNANT MESOTHELIOMA - PROGNOSTIC VARIABLES IN A REGISTRY OF 180 PATIENTS, THE DANA-FARBER-CANCER-INSTITUTE AND BRIGHAM-AND-WOMENS-HOSPITAL EXPERIENCE OVER 2 DECADES, 1965-1985 [J].
ANTMAN, K ;
SHEMIN, R ;
RYAN, L ;
KLEGAR, K ;
OSTEEN, R ;
HERMAN, T ;
LEDERMAN, G ;
CORSON, J .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (01) :147-153
[2]   CHROMOSOME CHANGES IN MALIGNANT MESOTHELIOMA [J].
GIBAS, Z ;
LI, FP ;
ANTMAN, KH ;
BERNAL, S ;
STAHEL, R ;
SANDBERG, AA .
CANCER GENETICS AND CYTOGENETICS, 1986, 20 (3-4) :191-201
[3]   CYTOGENETIC ANALYSIS OF MALIGNANT MESOTHELIOMA [J].
HAGEMEIJER, A ;
VERSNEL, MA ;
VANDRUNEN, E ;
MORET, M ;
BOUTS, MJ ;
VANDERKWAST, TH ;
HOOGSTEDEN, HC .
CANCER GENETICS AND CYTOGENETICS, 1990, 47 (01) :1-28
[4]   APPLICATION OF DNA FLOW-CYTOMETRY TO PARAFFIN-EMBEDDED ARCHIVAL MATERIAL FOR THE STUDY OF ANEUPLOIDY AND ITS CLINICAL-SIGNIFICANCE [J].
HEDLEY, DW ;
FRIEDLANDER, ML ;
TAYLOR, IW .
CYTOMETRY, 1985, 6 (04) :327-333
[5]  
HEIM S, 1987, CANCER CYTOGENETICS
[6]  
LUNDGREN R, 1991, UNPUB J UROL
[7]   ASBESTOS - SCIENTIFIC DEVELOPMENTS AND IMPLICATIONS FOR PUBLIC-POLICY [J].
MOSSMAN, BT ;
BIGNON, J ;
CORN, M ;
SEATON, A ;
GEE, JBL .
SCIENCE, 1990, 247 (4940) :294-301
[8]   DIPLOID PREDOMINANCE AND PROGNOSTIC-SIGNIFICANCE OF S-PHASE CELLS IN MALIGNANT MESOTHELIOMA [J].
PYRHONEN, S ;
LAASONEN, A ;
TAMMILEHTO, L ;
RAUTONEN, J ;
ANTTILA, S ;
MATTSON, K ;
HOLSTI, LR .
EUROPEAN JOURNAL OF CANCER, 1991, 27 (02) :197-200
[9]  
PYRHONEN S, IN PRESS CANCER GENE
[10]   CHROMOSOME CHANGES IN BLADDER-CANCER - CLINICAL AND OTHER CORRELATIONS [J].
SANDBERG, AA .
CANCER GENETICS AND CYTOGENETICS, 1986, 19 (1-2) :163-175